Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2013 Aug;98(8):1232-6.
doi: 10.3324/haematol.2012.083048. Epub 2013 May 3.

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Pier Luigi Zinzani  1 , Simonetta Viviani, Antonella Anastasia, Umberto Vitolo, Stefano Luminari, Francesco Zaja, Paolo Corradini, Michele Spina, Ercole Brusamolino, Alessandro M Gianni, Armando Santoro, Barbara Botto, Enrico Derenzini, Cinzia Pellegrini, Lisa Argnani
Affiliations
Observational Study

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Pier Luigi Zinzani et al. Haematologica. 2013 Aug.

Abstract

Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin's lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program in Italy (non trial-setting). The primary study endpoint was the objective response rate; secondary endpoints were safety, overall survival and progression-free survival. The best overall response rate (70.7%), including 21.5% complete responses, was observed at the first restaging after the third cycle of treatment. After a median follow up of 13.2 months, the overall survival rate at 20 months was 73.8% while the progression-free survival rate at 20 months was 24.2%. Globally nine patients are in continuous complete response with a median follow up of 14 months (range, 10-19 months). Four patients proceeded to autotransplantation and nine to allotransplantation. The most frequent extra-hematologic toxicity was peripheral neuropathy, observed in 21.5% of cases (9 patients with grade 1/2 and 5 patients with grade 3/4); neurological toxicity led to discontinuation of treatment in three patients and to dose reduction in four. In general the treatment was well tolerated and toxicities, both hematologic and extra-hematologic, were manageable. This report indicates and confirms that brentuximab vedotin as a single agent is effective and safe also when used in standard, everyday clinical practice outside a clinical trial. Best overall responses were recorded after three or four cycles and showed that brentuximab vedotin provides an effective bridge to further therapeutic interventions.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Algorithm of the responses at the PET3 and PET8 evaluations. CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: overall response rate.
Figure 2.
Figure 2.
Duration of complete response in alive patients. Black circles, allogeneic transplant; gray circles, autologous stem cell transplant.
Figure 3.
Figure 3.
(A) Overall survival and (B) progression-free survival.
Figure 4.
Figure 4.
Progression-free survival of patients divided according to response. CR: complete response; PR: partial response; SD: stable disease; pts, patients.
See this image and copyright information in PMC

References

    1. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327 (21):1478–84 - PubMed
    1. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP_ABVD for advanced Hodgkin’s disease. N Engl J Med. 2003;348:(7)2386–95 - PubMed
    1. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet. 1993;341(8852): 1051–4 - PubMed
    1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359(9323):2065–71 - PubMed
    1. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M, et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: A case-control study. J Clin Oncol. 1999;17 (1):222–9 - PubMed

Publication types